急性腎障害治療市場：製品タイプ、障害タイプ、エンドユーザー別-2025-2030年の世界予測

急性腎障害治療市場の2023年の市場規模は18億7,000万米ドルで、2024年には20億2,000万米ドルに達すると予測され、CAGR 7.81％で成長し、2030年には31億7,000万米ドルに達すると予測されます。

急性腎障害（AKI）治療は、突然の腎機能低下を管理するための効果的な治療介入の必要性に根ざした、ヘルスケア市場の発展セグメントです。AKI治療の必要性は、その高い罹患率と死亡率に起因しており、早期かつ正確な介入が極めて重要です。現在のアプリケーションは、腎回復の促進、体液バランス、電解質異常の管理、さらなる腎障害の最小化に重点を置いています。これらの治療は、病院、透析センター、集中治療室などで行われており、クリティカルケア環境全体における高い最終用途範囲を反映しています。この市場に影響を与える主な成長要因としては、糖尿病や高血圧などの慢性疾患の有病率の上昇、人口の高齢化、診断技術やモニタリング技術の進歩などが挙げられます。潜在的な治療機会は、幹細胞治療、次世代透析製品、AKI早期発見のためのバイオマーカーなど、患者の予後を大幅に改善できる革新的な治療法の開発にあります。企業は学術機関との共同研究を活用することで、技術革新を迅速に進め、治療ポートフォリオを拡大することができます。しかし、この市場は、高い治療費、熟練した腎臓専門医の不足、重症患者における多臓器不全の複雑な性質などの限界に直面しています。さらに、規制上の課題や広範な臨床検証の必要性により、製品の上市が遅れることもあります。このような課題にもかかわらず、AIを活用した予測分析、個別化医療アプローチ、新規の腎臓サポート機器などのイノベーション分野が、市場の大幅な成長への道を開く可能性があります。AKI治療市場は、技術開発と治療の進歩に重点を置いたダイナミックな性質が特徴です。市場力学に関する洞察は、企業が十分な情報に基づいた投資決定を下し、研究開発努力に優先順位をつけ、戦略的に協力するための指針となります。包括的な市場分析により、アンメットメディカルニーズへの対応と既存の治療効果の改善が、AKI治療における持続的な事業拡大に向けた極めて重要な道筋であることが明らかになりました。

市場力学：急速に進化する急性腎障害治療市場の主要市場インサイトを公開

急性腎障害治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 腎不全および腎臓関連疾患の増加
  • 腎障害治療薬の承認数の増加
  • 腎臓の健康に対する認識を高めるための政府の取り組み
• 市場抑制要因
  • 治療費の高騰と償還不足
• 市場機会
  • 腎臓治療の選択肢を増やし、病気の発見を向上させる治療法の進歩
  • 腎臓治療を提供する新しい病院と外来治療の改善
• 市場の課題
  • 特定の腎障害治療オプションに関する厳しい規制

ポーターのファイブフォース：急性腎障害治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：急性腎障害治療市場における外部からの影響の把握

外部マクロ環境要因は、急性腎障害治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析急性腎障害治療市場における競合情勢の把握

急性腎障害治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス急性腎障害治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、急性腎障害治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨急性腎障害治療市場における成功への道筋を描く

急性腎障害治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 腎不全および腎臓関連疾患の増加
    • 腎臓疾患の治療薬の承認件数が増加
    • 腎臓の健康に関する意識を高める政府の取り組み
  • 抑制要因
    • 治療費の高騰と払い戻しの欠如
  • 機会
    • 腎臓治療の選択肢を増やし、病気の検出を改善するための進歩
    • 腎臓治療を提供する新しい病院と外来診療の改善
  • 課題
    • 特定の腎障害治療オプションに関する厳格な規制
• 市場セグメンテーション分析
  • 製品：透析治療の改善に向けた調査活動の増加
  • 障害の種類：腎障害の根本的な原因についての認識が、内因性腎急性腎障害の治療法の開発につながる
  • エンドユーザー：外来ケアの改善により、外来手術センター（ASC）の普及が進む
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 急性腎障害治療市場：製品別

• 透析
  • 持続的腎代替療法（CRRT）
  • 間欠的血液透析
  • 持続的低効率透析（SLED）
• 薬物療法
  • 抗生物質
  • 利尿剤
  • 免疫抑制剤

第7章 急性腎障害治療市場傷害の種類別

• 内因性腎急性腎障害
• 腎後急性腎障害
• 腎前性急性腎障害

第8章 急性腎障害治療市場：エンドユーザー別

• 外来手術センター
• 病院

第9章 南北アメリカの急性腎障害治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の急性腎障害治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの急性腎障害治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ノバルティス、チヌークを最大35億米ドルで買収、腎臓病パイプラインを拡大
  • CalciMedica、Graybug Visionとの合併と同時私募の完了を発表
  • シースターメディカル、急性腎障害の成人の過炎症を軽減する選択的細胞除去装置の研究開始のFDA承認を取得
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alloksys Life Sciences B.V.
• Amgen Inc.
• Angion Biomedica Corp.
• Asahi Kasei Medical Co., Ltd.
• B. Braun Melsungen AG
• Baxter International, Inc.
• Bayer AG
• bioMerieux SA
• Dr. Reddys Laboratories Ltd.
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Reata Pharmaceuticals Inc. by Biogen Inc.
• Rockwell Medical, Inc.
• Silver Creek Pharmaceuticals, Inc.
• Stealth BioTherapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ACUTE KIDNEY INJURY TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACUTE KIDNEY INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACUTE KIDNEY INJURY TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 70. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 75. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 76. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 161. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 162. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 181. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 182. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 186. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Acute Kidney Injury Treatment Market was valued at USD 1.87 billion in 2023, expected to reach USD 2.02 billion in 2024, and is projected to grow at a CAGR of 7.81%, to USD 3.17 billion by 2030.

Acute Kidney Injury (AKI) treatment is an evolving segment in the healthcare market, rooted in the need for effective therapeutic interventions to manage sudden kidney function loss. The necessity of AKI treatment stems from its high morbidity and mortality rates, making early and accurate interventions crucial. Current applications focus on enhancing renal recovery, managing fluid balance, electrolyte disturbances, and minimizing further renal damage. These treatments serve hospitals, dialysis centers, and intensive care units, reflecting a high end-use scope across critical care settings. Key growth factors influencing this market include the rising prevalence of chronic diseases like diabetes and hypertension, an aging population, and advancements in diagnostic techniques and monitoring technologies. Potential opportunities lie in the development of innovative therapies such as stem-cell treatment, next-gen dialysis products, and biomarkers for early AKI detection, which can significantly enhance patient outcomes. Companies can leverage collaborative research with academic institutions to fast-track innovation and widen therapeutic portfolios. However, the market faces limitations including high treatment costs, the shortage of skilled nephrologists, and the complex nature of multi-organ failure in critical patients. Moreover, regulatory challenges and the need for extensive clinical validation can delay product launches. Despite these challenges, innovation areas such as AI-driven predictive analytics, personalized medicine approaches, and novel kidney support devices can pave the way for substantial market growth. The AKI treatment market is characterized by a dynamic nature, with a strong emphasis on technological developments and therapeutic advancements. Insights into market dynamics can guide businesses to make informed investment decisions, prioritize R&D efforts, and collaborate strategically. Comprehensive market analysis reveals that addressing unmet medical needs and improving existing treatment efficacy are pivotal pathways toward sustainable business expansion in the AKI treatment landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Kidney Injury Treatment Market

The Acute Kidney Injury Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of kidney failures and kidney-related diseases
  • Growing number of drug approvals for the treatment of kidney disorders
  • Government initiatives to raise awareness about kidney health
• Market Restraints
  • High cost of availing treatment and lack of reimbursements
• Market Opportunities
  • Advancements to enhance kidney treatment options and improve disease detection
  • New hospitals providing kidney treatment and improvements in outpatient care
• Market Challenges
  • Stringent regulations concerning certain kidney injury treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Acute Kidney Injury Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Kidney Injury Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Kidney Injury Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Kidney Injury Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Kidney Injury Treatment Market

A detailed market share analysis in the Acute Kidney Injury Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Kidney Injury Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Kidney Injury Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Kidney Injury Treatment Market

A strategic analysis of the Acute Kidney Injury Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Kidney Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alloksys Life Sciences B.V., Amgen Inc., Angion Biomedica Corp., Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Bayer AG, bioMerieux SA, Dr. Reddys Laboratories Ltd., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Reata Pharmaceuticals Inc. by Biogen Inc., Rockwell Medical, Inc., Silver Creek Pharmaceuticals, Inc., Stealth BioTherapeutics, Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Kidney Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Dialysis and Drug Therapy. The Dialysis is further studied across Continuous Renal Replacement Therapy (CRRT), Intermittent Hemodialysis, and Sustained Low-Efficiency Dialysis (SLED). The Drug Therapy is further studied across Antibiotics, Diuretics, and Immunosuppressive Agents.
• Based on Injury Type, market is studied across Intrinsic-Renal Acute Kidney Injury, Post-Renal Acute Kidney Injury, and Pre-Renal Acute Kidney Injury.
• Based on End-User, market is studied across Ambulatory Surgical Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of kidney failures and kidney-related diseases
    • 5.1.1.2. Growing number of drug approvals for the treatment of kidney disorders
    • 5.1.1.3. Government initiatives to raise awareness about kidney health
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of availing treatment and lack of reimbursements
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements to enhance kidney treatment options and improve disease detection
    • 5.1.3.2. New hospitals providing kidney treatment and improvements in outpatient care
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations concerning certain kidney injury treatment options
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising number of research initiatives to improve dialysis treatment
  • 5.2.2. Injury type: Awareness about underlying causes of kidney injury leading to the creation of treatments for Intrinsic-Renal Acute Kidney Injury
  • 5.2.3. End-user: Improvements in outpatient care leading to rising prevalence of ambulatory surgical centers (ASCs)
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Kidney Injury Treatment Market, by Product

• 6.1. Introduction
• 6.2. Dialysis
  • 6.2.1. Continuous Renal Replacement Therapy (CRRT)
  • 6.2.2. Intermittent Hemodialysis
  • 6.2.3. Sustained Low-Efficiency Dialysis (SLED)
• 6.3. Drug Therapy
  • 6.3.1. Antibiotics
  • 6.3.2. Diuretics
  • 6.3.3. Immunosuppressive Agents

7. Acute Kidney Injury Treatment Market, by Injury Type

• 7.1. Introduction
• 7.2. Intrinsic-Renal Acute Kidney Injury
• 7.3. Post-Renal Acute Kidney Injury
• 7.4. Pre-Renal Acute Kidney Injury

8. Acute Kidney Injury Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals

9. Americas Acute Kidney Injury Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Acute Kidney Injury Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Acute Kidney Injury Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Novartis to Buy Chinook for Up to USD 3.5 Billion, Expanding Kidney Disease Pipeline
  • 12.3.2. CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
  • 12.3.3. SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alloksys Life Sciences B.V.
• 3. Amgen Inc.
• 4. Angion Biomedica Corp.
• 5. Asahi Kasei Medical Co., Ltd.
• 6. B. Braun Melsungen AG
• 7. Baxter International, Inc.
• 8. Bayer AG
• 9. bioMerieux SA
• 10. Dr. Reddys Laboratories Ltd.
• 11. Fresenius Medical Care AG & Co. KGaA
• 12. GlaxoSmithKline PLC
• 13. Johnson & Johnson Services, Inc.
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Otsuka Pharmaceutical Co., Ltd.
• 17. Pfizer Inc.
• 18. Reata Pharmaceuticals Inc. by Biogen Inc.
• 19. Rockwell Medical, Inc.
• 20. Silver Creek Pharmaceuticals, Inc.
• 21. Stealth BioTherapeutics, Inc.
• 22. Teva Pharmaceutical Industries Ltd.